OPEN END TURBO OHNE STOP-LOSS - NOVO-NORDISK B | Market Closed - Börse Stuttgart 07:11:04 05/07/2024 BST | ||
| 1.34 EUR | +1.52% |
|
| Current month | -8.22% | ||
| 1 month | +0.75% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 05/07/24 | 1.34 | +1.52% |
| 04/07/24 | 1.32 | -5.71% |
| 03/07/24 | 1.4 | -4.76% |
| 02/07/24 | 1.47 | +2.80% |
| 01/07/24 | 1.43 | -2.05% |
Delayed Quote Börse Stuttgart
Last update July 05, 2024 at 07:11 am
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Lang & Schwarz |
| WKN | LX26EB |
| ISIN | DE000LX26EB9 |
| Date issued | 02/06/2023 |
| Strike | 62.12 € |
| Maturity | Unlimited |
| Parity | 50 : 1 |
| Emission price | 0.33 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.48 € |
|---|---|
| Lowest since issue | 0.2 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
974
DKK
Average target price
952.2
DKK
Spread / Average Target
-2.24%
- Stock Market
- Certificates
- Certificat
